This preprint introduces multistate enzyme design (MEnD), a computational framework that optimizes active-site sequences against four transition-state theozymes (TS1βTS4) placed on crystallographic conformational ensembles, rather than a single rigid transition state. Applied to the Morita-Baylis-Hillmanase BH32.12 scaffold, the best multistate variant BH32.M6 (9 active-site mutations) achieved kcat = 0.031 minβ»ΒΉ, KM,2CH = 0.84 mM, and a bi-substrate efficiency of 440 Mβ»Β² sβ»ΒΉ β >100-fold higher than single-state BH32.S8 (4 Mβ»Β² sβ»ΒΉ) and 2-fold higher than the directed-evolution enzyme BH32.12 (210 Mβ»Β² sβ»ΒΉ), while also improving enantioselectivity to 93% ee(R) vs 86% for BH32.12.
Mechanistic dissection supports the authors' interpretation that single-state optimization destabilized upstream states: BH32.S8 lost the kinetic isotope effect on proton transfer (TS3), showed a KSVE slope <0.5 (vs >0.5 for BH32.M6 and BH32.12), and had a 4-fold lower k_inact for Michael addition, collectively indicating the rate-limiting step migrated upstream of the targeted TS3. Crystallographic ensemble refinement showed BH32.M6 preserved productive His23 rotamers in 77% of conformers (vs 24% for BH32.S8) and lower modal Arg124 RMSDs to theozyme models for 3 of 4 transition states.
Strengths: The study is unusually rigorous for enzyme design work β global fitting to a random-order binding model, KIE/KSVE mechanistic probes, noncryogenic crystallography with ensemble refinement, and an honest head-to-head comparison including a deep-learning comparator (LigandMPNN). The LigandMPNN result (BH32.L7, 10-fold less efficient, inverted stereoselectivity at β11% ee) is a valuable negative result showing that structure-confidence filtering alone does not enforce energetic balance or stereochemical control. Structures (PDB 38GE/38GF/38GG) and ensemble data (Zenodo) are deposited, supporting reproducibility.
Limitations and blindspots: (1) The framework is demonstrated on only one enzyme family and one reaction coordinate; generality remains untested. (2) Only TS3 was used as the single-state comparator β it is possible that single-state design targeting a different TS would fare better, weakening the claim that single-state design is categorically inferior. (3) BH32.M6 is 2-fold better than BH32.12 in efficiency but its kcat (0.031 minβ»ΒΉ) remains ~2-fold lower than BH32.12 (0.058 minβ»ΒΉ); the efficiency gain comes primarily from improved KM for 2-cyclohexen-1-one, not from faster turnover. (4) The LigandMPNN implementation used a fixed homotetramer merge of theozyme-bound structures without iterative energetic rebalancing; a more sophisticated deep-learning baseline (e.g. coupling LigandMPNN with Triad rescoring) was not explored. (5) Small numbers of protein batches for some kinetic datasets (n=2 for BH32.8, n=2β3 for KIE) limit statistical power. (6) The BH32.S8 enantioselectivity could not be determined due to an aldol by-product, preventing a complete stereochemical comparison.
The central claim would be weakened if a single-state design variant achieved efficiency comparable to BH32.M6 while retaining TS3 as rate-limiting (significant KIE, KSVE slope β BH32.12). Given only one scaffold and one single-state target were tested, the broader claim that multistate optimization is generically superior should be treated as a well-supported but single-instance demonstration rather than a general law. Confidence in the head-to-head BH32.M6 vs BH32.S8 result is high (direct kinetic evidence, multiple mechanistic probes); confidence in generalizability is moderate.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.